Evidence map›Paper›PMID 29644071›Full record

ArticleClinical kidney journal2018

Clinical management of patients on peritoneal dialysis in Italy: results from the ATENA study.

Carlo Crepaldi, Alessandro Possidoni, Flavia Caputo, Roberto Dell'Aquila, Emilio Giulio Galli, Anna Maria Costanzo, Giuliana Gualberti, Umberto di Luzio Paparatti, Roberto Russo, ATENA Study Group

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Carlo CrepaldiDialisi e Trapianto Renale, ULSS6 di Vicenza Ospedale San Bortolo U.O.C. Nefrologia, Vicenza, Italy.
Alessandro PossidoniAbbVie Italy Srl, Campoverde di Aprilia (LT).
Flavia CaputoDialisi e Trapianto, A.R.N.A.S Osp. Civico di Cristina Benfratelli U.O. di Nefrologia 2°, Palermo, Italy.
Roberto Dell'AquilaAzienda ULSS 7 "PEDEMONTANA" Struttura Complessa di Nefrologia e Dialisi, Bassano del Grappa, Vicenza, Italy.
Emilio Giulio GalliAzienda Ospedaliera "Treviglio-Caravaggio" Nefrologia, Bergamo, Italy.
Anna Maria CostanzoAbbVie Italy Srl, Campoverde di Aprilia (LT).
Giuliana GualbertiAbbVie Italy Srl, Campoverde di Aprilia (LT).
Umberto di Luzio PaparattiAbbVie Italy Srl, Campoverde di Aprilia (LT).
Roberto RussoA.O.U. Policlinico di Bari U.O.C. di Nefrologia, Bari, Italy.
ATENA Study Group
Azienda di Rilievo Nazionale ed Alta Specializzazione · ITAzienda Ospedaliera Treviglio · ITOspedale San Bassiano · ITOspedale San Bortolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Italy, few studies have examined the clinical management of peritoneal dialysis (PD) patients, resulting in a lack of information and awareness.

methodsA total of 378 PD patients (64.7 ± 14.3 years, 58.9% males) were enrolled across 15 centres in a 12-month retrospective and 6-month prospective study. The primary objective was to evaluate the achievement of Kidney Disease Outcomes Quality Initiative and Kidney Disease Improving Global Outcomes guidelines on recommended target values for anaemia, high blood pressure and mineral metabolism. Comorbidities, hospitalizations, treatment and quality of life were also assessed.

resultsFrequent comorbidities included hypertension (87.8%) and cardiovascular disease (39.7%). Peritonitis was the leading cause of hospitalization [12 admissions per 100 person-years (95% confidence interval 9.3-15.2)]. At 6 months, anaemia corrected by erythropoiesis-stimulating agents was observed in 30% of patients and 73% received erythropoiesis-stimulating agents. Systolic and diastolic blood pressures were recorded in 50% and 20% of patients, respectively. Sixty-four percent of echocardiograms revealed left ventricular hypertrophy and 30% of patients had vitamin D <10 ng/mL. Medication to treat intact parathyroid hormone (PTH) included calcitriol (36.3%), paricalcitol (29.2%), cholecalciferol (23.6%) and cinacalcet (21.5%). In a subgroup of patients matched for baseline PTH treated for 1 year, a significant reduction in PTH with paricalcitol (-41%; P < 0.001) but not cinacalcet (+2%; P = 0.63) was observed. Comparison of quality of life domains revealed significant differences for symptoms (P = 0.049), cognitive function (P = 0.019) and social support (P = 0.04) (baseline versus 6 months).

conclusionsHypertension and cardiovascular diseases were frequent comorbidities and peritonitis was the leading cause of hospitalization. Secondary hyperparathyroidism and anaemia were common, thus necessitating frequent monitoring of PTH, calcium, phosphorus and haemoglobin.

Indexed as

anaemiachronic kidney diseasemetabolic bone disordersperitoneal dialysissecondary hyperparathyroidism

Identifiers

PMID29644071
PMCPMC5887992
OpenAlexW2795205356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.